U.S. Distributor Appointed For Bioniche's Immunocidin(TM) Canine Oncology Therapy

- Vedco, Inc. of St. Joseph, Missouri selected as U.S. distributor -

BELLEVILLE, ON, Nov. 21, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has appointed an exclusive U.S. distributor for its Immunocidin ^TM canine oncology therapy: St. Joseph, Missouri-based Vedco, Inc. Immunocidin ^TM was launched at the annual U.S. Veterinary Cancer Society conference in October of this year.

Immunocidin ^TM is based on the Company's proprietary mycobacterial cell wall technology, the same platform from which its Phase III product for human bladder cancer ( Urocidin ^TM ) was derived. Immunocidin ^TM is indicated as an immunotherapy for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs. The product has received regulatory approval in Canada and the U.S. and is expected to be launched in Canada in January, 2013.

Vedco will begin immediate distribution of Immunocidin ^TM to veterinarians via its group of member distributors which includes Butler Schein Animal Health, Merritt Veterinary Supply, Miller Veterinary Supply, MWI Veterinary Supply, Penn Veterinary Supply and Webster Veterinary Supply.

"We are pleased to have Vedco, Inc. as our U.S. distribution partner for this product," said Mr. Andrew Grant, President, Bioniche Animal Health (global). "Vedco is known for its broad and respected distribution network, comprising more than 1,000 sales representatives throughout the U.S."

Unlike commonly used canine oncology therapies, such as chemotherapy, Immunocidin ^TM does not require special handling and can be used by veterinarians in their own clinics, either alone or in combination with other therapies.

About Canine Cancer

Canine cancer is the leading disease-related cause of death in dogs, with approximately one in four dying of cancer.

1 2 Next › Last »